Bacteria are genetically changed to kill most cancer cells in mice via means of researchers.

In order to generate an immune response strong enough to eradicate an aggressive type of skin cancer, scientists at Stanford Medicine genetically engineer bacteria that are found on the fur of mice

By altering the bacteria and microbes that were found on the skin of mice, researchers at Stanford University were able to combat skin cancer.

Staphylococcus epidermidis, a bacteria found on the fur of mice,
was genetically engineered by Stanford Medicine researchers
to produce an immune response strong enough to kill an aggressive
form of metastatic skin cancer—a development that has
the potential to revolutionize cancer research and treatment.
All of this took place without causing any obvious inflammation.

Michael Fischbach, PhD, an Associate Professor of Bioengineering who

co-authored the research, stated, "It seemed almost like magic."

We applied a swab of bacteria to the fur of the heads of these mice,

who had very aggressive tumors growing on their flanks.

This was a gentle treatment.

Staph epidermidis were picked in the preliminary since they are

exceptional among colonizing microbes in setting off the development

of powerful resistant cells called CD8 Immune system microorganisms,

which are known to battle disease or extreme contaminations.

 

Even far from where it had been applied topically, the altered

bacteria was able to cause an immune response in the trial that

killed or reduced cancerous cells.

Fischbach continued, " Watching those cancers vanish — particularly at
a site far off from where we applied the microscopic organisms — was
stunning. It took us some time to believe it was taking place.

It is important to note that the researchers at Stanford do not yet
know if Staph epidermidis can trigger a strong immune response
comparable to that of humans, and trials on mice do not always end
in the same way as trials on humans. In their tests, the researchers also
substituted a prostate cancer antigen for the skin cancer antigen,
and they found that tumor growth significantly slowed down.

According to the researchers, this suggests that genetically
engineered bacteria that colonize skin can elicit a robust immune
response against other types of cancer.

Fischbach is hopeful that the human trials that are scheduled for the upcoming

years will be successful. Staph epidermidis thrives naturally on human skin.

According to him, the bug will be able to colonize humans more

effectively, which could result in an endless supply of tumor-specific T cells.